argenx (ARGX) Stock Forecast & Price Target

argenx is supported by a durable commercial engine, with 3Q26 global VYVGART sales of about $1.72B, up 14% q/q and 53% y/y and ahead of consensus, while continued uptake in MG and CIDP shows the franchise is still expanding. The company also has multiple near- and medium-term catalysts, including an IMNM sBLA expected by year-end, a pediatric gMG PDUFA date in February 2027, Phase III ADVANCE-NEXT data in primary ITP expected in 1H27, and empasiprubart MMN readout narrowed to December 2026. Fundamentally, the outlook stays positive because approvals, new formulations, and a broad pipeline in celiac disease, thyroid eye disease, and Sjogren's Disease diversify growth beyond Vyvgart and extend upside from innovation.

argenx is facing a negative outlook because the core investment case depends heavily on Vyvgart sales expansion, yet lower-than-anticipated adoption, sustained efficacy concerns, or an unforeseen safety signal could quickly undermine growth. Its broader pipeline also carries meaningful execution risk, with ongoing trials for efgartigimod and empasiprubart exposed to regulatory setbacks, competitive pressure, and long-term pricing pressure, while macro factors such as FX, inflation, shipping risks, and tariffs add further uncertainty. The stock’s recent volatility and the possibility that expansion into oMG, ITP, myositis, and Sjogren’s fails would weaken platform value and leave investors with limited downside protection.